MS treatment showdown: which drug wins on cost and disability?
NCT ID NCT01065727
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 144 people with aggressive relapsing multiple sclerosis to compare two treatment plans over three years: monthly natalizumab infusions versus a six-month course of mitoxantrone followed by another immune-modulating drug. Researchers measured cost-effectiveness, disability progression, and quality of life. The goal was to find which strategy offers better value and outcomes for patients with this severe form of MS.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
natalizumab and mitoxantrone
What this could lead to
If successful, this could help doctors choose the most cost-effective and disability-slowing treatment for aggressive multiple sclerosis.
What could go wrong
This is a completed cost-effectiveness study, not a new drug trial. Results may not apply to all MS patients, and both treatments have known risks like infections or heart damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Cavale Blanche
Brest, 29609, France
-
CHU Rennes
Rennes, 35033, France